A substantial increase in the levels of glucagon-like peptide 1 (GLP-1), one of the brain-gut peptides promoting the glucose-dependent release of insulin and the inhibition of glucagon secretion, has been observed in T2DM patients treated with sotagliflozin, an agent that inhibits both SGLT-1 in the gastro-intestinal tract and SGLT-2 in the kidney. The gene discussed is SLC5A1; the disease is type 2 diabetes mellitus.